$80,000 of BIO-RAD LABORATORIES lobbying was just disclosed, from Q4 of 2025, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to biomedical research and development; Issues related to pathogen surveillance. Issues related to biomedical research and development; Issues related to pathogen surveillance. Issues related to advanced diagnostic testing and laboratory tools."
You can find more data on corporate lobbying on Quiver Quantitative.
BIO Hedge Fund Activity
We have seen 181 institutional investors add shares of BIO stock to their portfolio, and 188 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC added 777,593 shares (+4642.6%) to their portfolio in Q3 2025, for an estimated $218,029,301
- CAPITAL RESEARCH GLOBAL INVESTORS added 418,355 shares (+inf%) to their portfolio in Q3 2025, for an estimated $117,302,558
- SELECT EQUITY GROUP, L.P. removed 255,989 shares (-100.0%) from their portfolio in Q3 2025, for an estimated $71,776,755
- FULLER & THALER ASSET MANAGEMENT, INC. added 237,903 shares (+inf%) to their portfolio in Q3 2025, for an estimated $66,705,622
- MILLENNIUM MANAGEMENT LLC removed 227,393 shares (-90.3%) from their portfolio in Q3 2025, for an estimated $63,758,723
- MANGROVE PARTNERS IM, LLC added 126,853 shares (+inf%) to their portfolio in Q3 2025, for an estimated $35,568,312
- BOSTON TRUST WALDEN CORP added 95,448 shares (+inf%) to their portfolio in Q3 2025, for an estimated $26,762,664
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BIO Analyst Ratings
Wall Street analysts have issued reports on $BIO in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Buy" rating on 10/30/2025
- RBC Capital issued a "Outperform" rating on 08/01/2025
To track analyst ratings and price targets for BIO, check out Quiver Quantitative's $BIO forecast page.
BIO Price Targets
Multiple analysts have issued price targets for $BIO recently. We have seen 3 analysts offer price targets for $BIO in the last 6 months, with a median target of $375.0.
Here are some recent targets:
- Patrick Donnelly from Citigroup set a target price of $375.0 on 10/30/2025
- Brandon Couillard from Wells Fargo set a target price of $340.0 on 10/30/2025
- Conor McNamara from RBC Capital set a target price of $409.0 on 08/01/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
